Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.

Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones PM, Djaballah H, Clarkson B, Larson SM.

J Med Chem. 2007 Nov 15;50(23):5853-7. Epub 2007 Oct 23.

PMID:
17956080
2.

Dasatinib.

Lindauer M, Hochhaus A.

Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. Review.

PMID:
20072833
3.

Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.

Montero JC, Seoane S, Ocaña A, Pandiella A.

Clin Cancer Res. 2011 Sep 1;17(17):5546-52. doi: 10.1158/1078-0432.CCR-10-2616. Epub 2011 Jun 13. Review.

5.

Dasatinib: an anti-tumour agent via Src inhibition.

Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V.

Curr Drug Targets. 2011 Apr;12(4):563-78. Review.

PMID:
21226671
6.
7.

Novel dual Src/Abl inhibitors for hematologic and solid malignancies.

Schenone S, Brullo C, Musumeci F, Botta M.

Expert Opin Investig Drugs. 2010 Aug;19(8):931-45. doi: 10.1517/13543784.2010.499898. Review.

PMID:
20557276
8.

Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.

Quintás-Cardama A, Kantarjian H, Cortes J.

Future Oncol. 2006 Dec;2(6):655-65. Review.

PMID:
17155893

Supplemental Content

Support Center